 Cisplatin treatment non-small cell lung cancer Southwest Oncology Group study Novobiocin available oral antibiotic DNA topoisomerase II manner cell culture cytotoxicity agents cisplatin Thirty-six patients Phase II trial high-dose cisplatin days cycles steady-state dosing novobiocin mg capsules hours doses dose cisplatin patient study response complete responses patients partial responses additional patient unconfirmed partial response median survival time patients months results comparable concurrent Southwest Oncology Group SWOG Phase II III trials high-dose cisplatin non-small cell lung cancer NSCLC Novobiocin plasma levels patients optimal concentration cell culture potentiation cytotoxicity optimum test novobiocin modulator cytotoxicity availability intravenous preparation